Atlas Venture
Onward and Upward, 2024 Newsletter
border
Headline News
Atlas Venture Fund XIV: New $450M fund to support company creation and investments in groundbreaking biotechs
Press Release: Atlas Venture Fund XIV
Aiolos Bio Logo

acquired by

GSK Logo

for $1B upfront +
up to $400M in
potential milestones

Mariana Oncology Logo

acquired by

Novartis Logo

for $1B upfront +
up to $750M in potential
milestones

NEW DRUG APPROVED: Ojemda™ by Day One Biopharmaceuticals with logos
IFM Therapeutics Logo

Novartis exercised IFM Due acquisition option

border
New faces at Atlas
Meet some of our newest team members
Justin Feng

Justin Feng

Senior Associate

Julia Pian

Julia Pian

Associate

Bob Copeland

Bob Copeland

 

Venture Partner

Praveen Tipirneni

Praveen Tipirneni

Venture Partner

Akshay Vaishnaw

Akshay Vaishnaw

 

Venture Partner

Meet some of our newest EIRs and CEOs
Chris Cortis

Chris Cortis

 

Entrepreneur-in-Residence

John Cox

John Cox

CEO

Dyne Therapeutics

Pascal Fortin

Pascal Fortin

 

Entrepreneur-in-Residence

Eric Green

Eric Green

CEO

Trace Neuroscience

Alex Harding

Alex Harding

 

Entrepreneur-in-Residence

Rob Henderson

Rob Henderson

 

Entrepreneur-in-Residence

Niranjan Kameswaran

Niranjan
Kameswaran

Entrepreneur-in-Residence

Nick Keen

Nick Keen

 

Entrepreneur-in-Residence

Rajiv Patni

Rajiv Patni

CEO

Judo Bio

Tim Reilly

Tim Reilly

 

Entrepreneur-in-Residence

Ron Renaud

Ron Renaud

CEO

Kailera Therapeutics

Haojing Rong

Haojing Rong

 

Entrepreneur-in-Residence

Alfica Sehgal

Alfica Sehgal

 

Entrepreneur-in-Residence

Anthony Slavin

Anthony Slavin

 

Entrepreneur-in-Residence

Cody Tranbarger

Cody Tranbarger

 

Entrepreneur-in-Residence

Jeff Walsh

Jeff Walsh

CEO

nChroma Bio

New Startup Spotlights - Check out some of our recently launched portfolio companies - 5 Companies Launched out of Stealth Mode
Diagonal Therapeutics logo Judo Bio logo Kailera logo
Lifordi Immunotherapeutics logo Trace Neuroscience logo
Clinical Updates - 16 Companies with new clinical study initiations/data - Phase 1
Aavantgarde logo Accent Therapeutics logo Be Biopharma logo
Disc Medicine logo Dyne Therapeutics logo K36 Therapeutics logo
Kinaset Therapeutics logo Korro Bio logo Kymera logo
Obsidian Therapeutics logo Pheon Therapeutics logo Q32 Bio logo
Remix Therapeutics logo Scorpion logo Sionna logo
Third Harmonic Bio logo
Financings and BD - Advancing therapeutic programs with new capital and strategic collaborations
10 public companies raised >$2.5B in follow-on financings
Akero logo Day One Biopharmaceuticals logo
Disc Medicine logo Dyne Therapeutics logo
Korro Bio logo Kymera logo
Laminar Therapeutics logo Q32 Bio logo
Replimune logo Vigil logo
8 private companies raised >$950M
Be Therapeutics logo nChroma Bio logo
Obisian Therapeutics logo Pheon Therapeutics logo
Remix Therapeutics logo Scorpion logo
Sionna logo Triveni Bio logo
5 companies established SIGNIFICANT collaborations with >$2.5B potential total value
Arkuda Therapeutics Bio & Johnson & Johnson logo
Day One Biopharmaceuticals Logo & Ipsen Logo
Day One Biopharmaceuticals Logo & Mabcare Logo
Korro Bio Logo & Novo Nordisk Logo
Sionna Logo & AbbVie
Triana Logo & Pfizer Logo
Atlas Highlights

Atlas Portfolio Companies are Hiring

Visit our careers page today

View Careers

Atlas Team Promotions

Maurizio Fazio, MD

Principal

Meet Maurizio

Sarah Coughlin

VP of Human Recources

Meet Sarah

Science2Startup registration will open in the spring

Email info@science2startup.com to request an invitation

Atlas Perspectives

2024 Year In Review

Our annual presentation on the year in biotech presented by Bruce Booth

Watch Recording

Atlas XIV and Reflections on the VC Math Problem

LifeSciVC post by Bruce Booth

Read Article

A Primer on Early-Stage Biotech VC

From the Trenches Post by Aimee Raleigh, Principal, Atlas Venture

Read Article

Reflections on My Experience as a Board Member

From the Trenches post by Ivana Magovčević-Liebisch, CEO, Vigil Neuroscience

Read Article

Biotech Risk Cycles: Assets And Platforms

LifeSciVC post by Bruce Booth

Read Article
Atlas Venture Atlas Atlas Twitter